Cancer Epidemiology
Head of Section
Professor Henrik Møller
The Cancer Epidemiology Section incorporates researchers working on clinical epidemiology, ie research on the outcome of diagnostic procedures, tumour treatment, and support for cancer patients. The research program covers studies in breast, lung and prostate cancer and malignant melanoma.
The Epidemiology Section includes the Department of Health supported Thames Cancer Registry and the Cancer Epidemiology group. The Thames Cancer Registry is a unique cancer data resource, drawing upon the exceptional ethnic diversity of the population within its catchment area.
Head of Cancer Epidemiology Group
Professor Lars Holmberg
The Cancer Epidemiology group focuses on clinical epidemiology, i.e. research into the outcome of diagnostic procedures, tumour treatment, and support for cancer patients. The research programme covers studies in breast, lung and prostate cancers, malignant melanoma and molecular epidemiology. Several of the studies involve translational research strategies in that they incorporate measurements from modern tumour biology, such as genetic data and proteomics, in clinical outcome studies.
The metabolic syndrome and risk of urological cancers, treatment side-effects of prostate cancer, outcome after watchful waiting for early prostate cancer, biomarkers for lung cancer progression and for death in malignant melanoma, and patterns of management of lung cancer are some of the focus areas of ongoing projects, as well as a number of different aspects of breast cancer. These include risk of local recurrence after breast conserving therapy, influence of a local recurrence on survival, time trends in presentation, tumour characteristics and results of treatment, as well as risk factors for contralateral breast cancer.
The group works closely with different Sections within the Division of Cancer Studies, which includes the Thames Cancer Registry and Research Oncology, as well as with clinical colleagues within the Biomedical Research Centre of King’s Health Partners. The Group is supported by Cancer Research UK and Prostate Action.
Externally, the group collaborates with researchers in Scandinavia as well as the Harvard School of Public Health and Harvard Medical School in Boston.